UK drugmaker GlaxoSmithKline (LSE: GSK) reported sales for the third quarter of £9.08 billion ($12.47), an increase of 5% on the same period in 2020 and ahead of the £8.7 billion predicted by analysts.
Pharmaceutical revenue was up 5% at £4.4 billion, with sales from the oncology, immuno-inflammation and respiratory product areas all up by more than 30%. Sales from GSK’s Vaccines unit jumped by 7.7% to £2.2 billion.
"Double-digit sales growth in Pharmaceuticals and Vaccines"The Consumer Healthcare division, which will split from GSK in a de-merger planned for mid-2022, delivered quarterly sales of £2.5 billion, a 3% rise.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze